Engineered CAF-cancer cell hybrid membrane biomimetic dual-targeted integrated platform for multi-dimensional treatment of ovarian cancer
These new therapeutic nanoparticles can simultaneously target tumor cells, CAFs, immune cells, and the extracellular matrix, thereby increasing treatment sensitivity and improving the TME. Therefore, these TME-regulating nanoparticles, combining specificity, efficiency, and effectiveness, provide new insights into ovarian cancer treatment.
Authors
- Yingchao Zhao (ORCID: https://orcid.org/0000-0002-1979-2816)
- Yuwei Yao
- Shuangshuang Cheng
- Shuangge Liu
- Haojia Li (ORCID: https://orcid.org/0009-0008-2396-4562)
- Jiarui Zhang (ORCID: https://orcid.org/0000-0003-4776-852X)
- Hongbo Wang (ORCID: https://orcid.org/0000-0002-5271-1803)
- Yingying Peng (ORCID: https://orcid.org/0000-0003-4611-0873)
- Jin-Hua Chen (ORCID: https://orcid.org/0009-0000-6531-9301)
- Ting Zhou (ORCID: https://orcid.org/0000-0003-4573-9872)
- Kexin Huang (ORCID: https://orcid.org/0000-0002-9356-685X)
Institutions
- Union Hospital (HK)
- Huazhong University of Science and Technology (CN)
Publication Details
- Journal
- Journal of Nanobiotechnology
- Published
- 2025-02-05
- DOI
- https://doi.org/10.1186/s12951-025-03165-9
- Citations
- 13
- Primary Topic
- Proteoglycans and glycosaminoglycans research
- Type
- article
- Field-Weighted Citation Impact
- 14.97
Funders
- National Natural Science Foundation of China
- National Key Research and Development Program of China
- Fundamental Research Funds for the Central Universities